First-Line BOT/BAL Immunotherapy Shows Promise in MSS Colorectal Cancer: Science Fiction or New Reality?
At the American Association for Cancer Research (AACR) 2026 annual meeting, BBOpCo presented preliminary data showing that first-line treatment with BOT/BAL — a novel bispecific antibody therapy — demonstrated significant ... Read More